IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stake Boosted by Vanguard Group Inc.

Vanguard Group Inc. boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,078,084 shares of the company's stock after acquiring an additional 282,936 shares during the period. Vanguard Group Inc. owned about 5.88% of IDEAYA Biosciences worth $130,507,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Rhumbline Advisers lifted its stake in IDEAYA Biosciences by 0.5% in the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock valued at $2,919,000 after buying an additional 585 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after acquiring an additional 853 shares in the last quarter. Assetmark Inc. boosted its stake in shares of IDEAYA Biosciences by 2.5% during the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock valued at $1,163,000 after acquiring an additional 1,084 shares during the last quarter. R Squared Ltd purchased a new stake in IDEAYA Biosciences during the 4th quarter worth about $35,000. Finally, Handelsbanken Fonder AB raised its stake in IDEAYA Biosciences by 8.1% in the 4th quarter. Handelsbanken Fonder AB now owns 25,300 shares of the company's stock valued at $650,000 after purchasing an additional 1,900 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Trading Up 6.2 %

NASDAQ IDYA traded up $0.98 during mid-day trading on Friday, reaching $16.75. 1,555,053 shares of the company's stock traded hands, compared to its average volume of 924,816. The company has a fifty day simple moving average of $18.86 and a 200-day simple moving average of $24.30. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -5.08 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analysts' expectations of $7.00 million. Equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Stephens reissued an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.